[go: up one dir, main page]

WO2009065604A3 - Pharmaceutical composition comprising glucosamine sulfate, chondroitine sulfate and ibuprofene - Google Patents

Pharmaceutical composition comprising glucosamine sulfate, chondroitine sulfate and ibuprofene Download PDF

Info

Publication number
WO2009065604A3
WO2009065604A3 PCT/EP2008/009897 EP2008009897W WO2009065604A3 WO 2009065604 A3 WO2009065604 A3 WO 2009065604A3 EP 2008009897 W EP2008009897 W EP 2008009897W WO 2009065604 A3 WO2009065604 A3 WO 2009065604A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulfate salt
pharmaceutical composition
sulfate
ibuprofen
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/009897
Other languages
French (fr)
Other versions
WO2009065604A2 (en
Inventor
Anna Bozhek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Consumer Care AG
Original Assignee
Bayer Consumer Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EA200702569A external-priority patent/EA200702569A1/en
Application filed by Bayer Consumer Care AG filed Critical Bayer Consumer Care AG
Priority to EA201000810A priority Critical patent/EA019542B1/en
Priority to UAA201007842A priority patent/UA103309C2/en
Publication of WO2009065604A2 publication Critical patent/WO2009065604A2/en
Publication of WO2009065604A3 publication Critical patent/WO2009065604A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the field of medicine and, more particularly, to drugs for internal use to treat a pain syndrome during a pain exacerbation phase in primary osteoarthrosis and secondary osteoarthrosis and other degenerative dystrophic diseases of extremity joints and intervertebral disks. The pharmaceutical composition for oral administration comprises chondroitin sulfate salt and glycosamine sulfate salt, ibuprofen as a nonsteroidal anti-inflammatory drug, and auxiliary substances wherein the ingredients are comprised in the following ingredient ratio (% w/w): Chondroitin sulfate salt 20 to 30 Glucosamine sulfate salt 30 to 36 Ibuprofen 10 to 15 and auxiliary substances Q. S. The present invention provides a pharmaceutical composition which ensures a chondroprotective, anti-inflammatory, and analgetic effect, an effective treatment of degenerative dystrophic diseases of extremity joints and intervertebral disks, a convenience of using the medicine, decrease in side effect risks, and the provision of an alternative medicament.
PCT/EP2008/009897 2007-11-23 2008-11-21 Pharmaceutical composition comprising glucosamine sulfate, chondroitine sulfate and ibuprofene Ceased WO2009065604A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EA201000810A EA019542B1 (en) 2007-11-23 2008-11-21 PHARMACEUTICAL COMPOSITION
UAA201007842A UA103309C2 (en) 2007-11-23 2008-11-21 Pharmaceutical composition for oral administration comprises chondroitin sulfate salt and glycosamine sulfate salt, ibuprofen

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
UA2007012960 2007-11-23
UA200712960 2007-11-23
EA200702569 2007-12-20
EA200702569A EA200702569A1 (en) 2007-12-20 2007-12-20 PHARMACEUTICAL COMPOSITION

Publications (2)

Publication Number Publication Date
WO2009065604A2 WO2009065604A2 (en) 2009-05-28
WO2009065604A3 true WO2009065604A3 (en) 2009-10-08

Family

ID=40525286

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/009897 Ceased WO2009065604A2 (en) 2007-11-23 2008-11-21 Pharmaceutical composition comprising glucosamine sulfate, chondroitine sulfate and ibuprofene

Country Status (2)

Country Link
EA (1) EA019542B1 (en)
WO (1) WO2009065604A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2742172C2 (en) * 2017-06-30 2021-02-02 Общество с ограниченной ответственностью "ФБК" Combination of a chondroprotective agent with an nsaid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099013A1 (en) * 2000-01-24 2003-12-04 Omni Nutraceuticals, Inc. Acetaminophen/non-steroidal anti-inflamatory drug-glucosamine composition
RU2260432C1 (en) * 2004-10-12 2005-09-20 Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") Agent for treatment of articulation diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099013A1 (en) * 2000-01-24 2003-12-04 Omni Nutraceuticals, Inc. Acetaminophen/non-steroidal anti-inflamatory drug-glucosamine composition
RU2260432C1 (en) * 2004-10-12 2005-09-20 Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") Agent for treatment of articulation diseases
UA78917C2 (en) * 2004-10-12 2007-04-25 Open Joint Stock Company Nyzhn Agent for treatment of articulation diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200570, Derwent World Patents Index; AN 2005-681647, XP002540530 *
DEAL C L ET AL: "NUTRACEUTICALS AS THERAPEUTIC AGENTS IN OSTEOARTHRITIS THE ROLE OF GLUCOSAMINE, CHONDROITIN SULFATE, AND COLLAGEN HYDROLYSATE", RHEUMATIC DISEASES CLINICS OF NORTH AMERICA, W.B. SAUNDERS, PHILADELPHIA, PA, US, vol. 25, no. 2, 1 May 1999 (1999-05-01), pages 379 - 395, XP009050485, ISSN: 0889-857X *

Also Published As

Publication number Publication date
WO2009065604A2 (en) 2009-05-28
EA201000810A1 (en) 2010-12-30
EA019542B1 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
RU2470016C2 (en) Bipirazole derivative
WO2007112274A3 (en) Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
HRP20230272T1 (en) PROCEDURES FOR THE TREATMENT OF CYSTIC FIBROSIS
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
WO2008027350A3 (en) Acetaminophen pharmaceutical compositions
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
WO2008064192A3 (en) Modified release analgesic suspensions
SI2529622T1 (en) Bruton tyrosine kinase inhibitors
WO2008060764A3 (en) Topical therapies for oral mucositis and other conditions
DE602007002154D1 (en) Analgesic composition of topically applied, non-steroidal and anti-inflammatory drugs and opioids
Lee et al. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
WO2005035485A3 (en) Analgesic compounds, their synthesis and pharmaceutical compositions containing them
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
US20190374491A1 (en) Topical preparation for pain relief
WO2008092072A3 (en) Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
AU2009304002B9 (en) A medicinal product and treatment
CA2476939A1 (en) Pharmaceutical combinations of cox-2 inhibitors and opiates
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2009065604A3 (en) Pharmaceutical composition comprising glucosamine sulfate, chondroitine sulfate and ibuprofene
UA103309C2 (en) Pharmaceutical composition for oral administration comprises chondroitin sulfate salt and glycosamine sulfate salt, ibuprofen
WO2007144889A3 (en) Treatment of neurofibromatosis
WO2020036478A3 (en) Synergistic pharmaceutical composition comprising aceclofenac and betamethasone for the treatment of pain in localised forms of rheumatic illnesses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08852073

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201000810

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201007842

Country of ref document: UA

122 Ep: pct application non-entry in european phase

Ref document number: 08852073

Country of ref document: EP

Kind code of ref document: A2